Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 50,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Withdrawn Phase 1Phase 2 Interventional

Study of the Acute Effects of Triheptanoin in Heart Failure

NCT01787851
View directory record Official record
Conditions
Congestive Heart Failure, Non-ischemic Cardiomyopathy
Interventions
Triheptanoin oil
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

NCT01264302
View directory record Official record
Conditions
Healthy
Interventions
Finasteride
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

NCT02053753
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Denosumab CP4, Denosumab CP2
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Early Phase 1 Interventional Results available

Sensory and Opioid Mechanisms of Affective Touch

NCT03096353
View directory record Official record
Conditions
Pain, Touch
Interventions
Placebo, Naloxone
Other · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 29, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

NCT04103645
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Vactosertib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975
View directory record Official record
Conditions
Hookworm Infections
Interventions
Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
Biological · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

NCT00662675
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
Interventions
Pancrease MT 10.5, or MT 21, Placebo for Pancrease MT 10.5 or MT 21
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
7 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

NCT00057512
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
M4N
Drug
Lead sponsor
Erimos Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

NCT03452228
View directory record Official record
Conditions
Severe Hypertriglyceridemia (sHTG)
Interventions
evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Boca Raton, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 4 Interventional Results available

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty

NCT02255500
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine FNB, EXPAREL Infiltration
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 29, 2026, 4:19 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

NCT06672900
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Carbamazepine, Itraconazole (Sporanox), ALG-000184
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 29, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Danazol for the Treatment of Telomere Related Diseases

NCT03312400
View directory record Official record
Conditions
Telomere Disease
Interventions
Danazol
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

Employment-based Reinforcement of Naltrexone Ingestion and Abstinence

NCT00149669
View directory record Official record
Conditions
Cocaine-Related Disorders, Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
employment-based reinforcement
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 29, 2026, 4:19 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

NCT00424866
View directory record Official record
Conditions
Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Interventions
FGF-1, Placebo
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Not applicable Interventional

Renal Effects of Melatonin Trial in Chronic Kidney Disease

NCT04336566
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 4:19 AM EDT
Withdrawn Phase 1 Interventional

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

NCT02238522
View directory record Official record
Conditions
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Interventions
ZEN003365
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 29, 2026, 4:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

NCT01133756
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Lenvatinib, Carboplatin, Gemcitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 4:19 AM EDT
Recruiting Phase 2 Interventional

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

NCT06843551
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
Radiation · Drug
Lead sponsor
Benjamin Spieler
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Completed No phase listed Observational

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions

NCT03213951
View directory record Official record
Conditions
Prostate Cancer
Interventions
Experimental beta probe, PSMA-PET
Other · Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 29, 2026, 4:19 AM EDT
Completed No phase listed Observational

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

NCT03017729
View directory record Official record
Conditions
Lower Limb Spasticity
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Washington D.C., District of Columbia • Miami, Florida • North Palm Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Early Phase 1 Interventional Results available

Neuroendocrine Risk for PTSD in Women

NCT03973229
View directory record Official record
Conditions
PTSD, Trauma
Interventions
Estradiol patch, Placebo patch
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 29, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

NCT05268302
View directory record Official record
Conditions
Dengue
Interventions
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 29, 2026, 4:19 AM EDT